ATTR Amyloidosis Behandlungsmarkt GRÖSSEN- UND MARKTANTEILSANALYSE - WACHSTUMSTRENDS UND PROGNOSEN (2024 - 2031)
ATTR Amyloidosis Behandlungsmarkt wird nach Typ segmentiert (Hereditary ATTR Amyloidosis, Wildtyp ATTR Amyloidosis), Durch Behandlung (Pharmacological Therapies, Organtransplantation, Supportive Care), By Route of Administration(Oral, Intravenous, Subcutaneous), By End User (Hospitals, Specialty Clinics, Homecare Settings), By Geography America, Middle America, USA, USA, USA, USA, USA, USA Der Bericht bietet den Wert (in Mrd. USD) für die oben genannten Segmente.
Competitive overview of ATTR Amyloidosis Behandlungsmarkt
Zu den wichtigsten Akteuren des ATTR Amyloidosis Treatment Market gehören Pfizer Inc., Alnylam Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Eidos Therapeutics, Inc., Akcea Therapeutics, Inc., Prothena Corporation plc, Corino Therapeutics, Inc. und AstraZeneca plc.
ATTR Amyloidosis Behandlungsmarkt Leaders
- Pfizer Inc.
- Alnylam Pharmaceuticals, Inc.
- Ionis Pharma, Inc.
- Eidos Therapeutics, Inc.
- Akcea Therapeutics, Inc.
ATTR Amyloidosis Behandlungsmarkt - Competitive Rivalry, 2023
ATTR Amyloidosis Behandlungsmarkt
(Dominated by major players)
(Highly competitive with lots of players.)